Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer.

[1]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[2]  A. Ballestrero,et al.  Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry , 2013, Bone Marrow Transplantation.

[3]  H. Takeyama,et al.  Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review , 2012, Breast Cancer.

[4]  I. Weissman,et al.  Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  D. Berry,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[7]  E. Winer,et al.  International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? , 2010, Journal of the National Cancer Institute.

[8]  T. Delozier,et al.  Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer , 2008, Bone Marrow Transplantation.

[9]  J. Dancey,et al.  Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Goldstein,et al.  Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial , 2006 .

[11]  Massimo Cristofanilli,et al.  Combined‐modality treatment for isolated recurrences of breast carcinoma , 2005, Cancer.

[12]  T. Delozier,et al.  High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. , 2005, European journal of cancer.

[13]  J. Ragaz,et al.  Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Shpall,et al.  Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Hortobagyi,et al.  Fluorouracil, Doxorubicin, and Cyclophosphamide Followed by Tamoxifen as Adjuvant Treatment for Patients with Stage IV Breast Cancer with No Evidence of Disease , 2002, The breast journal.

[17]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[18]  Amela,et al.  CONVENTIONAL-DOSE CHEMOTHERAPY COMPARED WITH HIGH-DOSE CHEMOTHERAPY PLUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR METASTATIC BREAST CANCER , 2000 .

[19]  G. Hortobagyi,et al.  Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Trudeau.  First‐line treatment of metastatic breast cancer , 1996, Anti-cancer drugs.

[21]  R. Mick,et al.  High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Teicher,et al.  A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Bast,et al.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Hortobagyi,et al.  Combined modality approach in breast cancer with isolated or multiple metastases , 1984, American journal of clinical oncology.

[25]  E. Frei,et al.  Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.

[26]  G. Hortobagyi,et al.  Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED) , 1979, Journal of surgical oncology.